Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative | $53.0K | $35.2K |
| Professional fees | $23.4K | $60.6K |
| Total operating expenses | $76.4K | $95.8K |
| Loss from operations | -$76.4K | -$95.8K |
| Loss before provision for income taxes | -$76.4K | -$95.8K |
| Net Loss | -$76.4K | -$95.8K |
| Loss Per Share, Basic | $0.00 | $0.00 |
| Loss Per Share,Diluted | $0.00 | $0.00 |
| Weighted Average Common Shares Outstanding, Basic | 1.0B shares | 1.0B shares |
| Weighted Average Common Shares Outstanding, Diluted | 1.0B shares | 1.0B shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $1.9K | $2.1K | |
| Prepaid expenses | $19.1K | $15.9K | |
| Total current assets | $21.0K | $17.9K | |
| Total Assets | $21.0K | $17.9K | |
| Due to related party | $318.6K | $239.2K | |
| Total Current Liabilities | $318.6K | $239.2K | |
| Total Liabilities | $318.6K | $239.2K | |
| Preferred Stock; par value $0.0001; 15,000,000 shares authorized; 15,000,000 shares issued and outstanding | $1.5K | $1.5K | |
| Common Stock; par value $0.0001; 2,700,000,000 shares authorized; 1,047,549,224 shares issued and outstanding | $104.8K | $102.2K | |
| Additional paid-in capital | $8.6M | $8.6M | |
| Accumulated deficit | -$9.0M | -$8.9M | |
| Total Stockholders' Deficit | -$297.6K | -$221.2K | -$82.1K |
| Total Liabilities and Stockholders' Deficit | $21.0K | $17.9K | |
| Preferred Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 15.0M shares | 15.0M shares | |
| Preferred Stock, Shares Issued | 15.0M shares | 15.0M shares | |
| Preferred Stock, Shares Outstanding | 15.0M shares | 15.0M shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 2.7B shares | 2.7B shares | |
| Common Stock, Shares, Issued | 1.0B shares | 1.0B shares | |
| Common Stock, Shares, Outstanding | 1.0B shares | 1.0B shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $1.9K | $2.1K | |
| Prepaid expenses | $19.1K | $15.9K | |
| Total current assets | $21.0K | $17.9K | |
| Total Assets | $21.0K | $17.9K | |
| Due to related party | $318.6K | $239.2K | |
| Total Current Liabilities | $318.6K | $239.2K | |
| Total Liabilities | $318.6K | $239.2K | |
| Preferred Stock; par value $0.0001; 15,000,000 shares authorized; 15,000,000 shares issued and outstanding | $1.5K | $1.5K | |
| Common Stock; par value $0.0001; 2,700,000,000 shares authorized; 1,047,549,224 shares issued and outstanding | $104.8K | $102.2K | |
| Additional paid-in capital | $8.6M | $8.6M | |
| Accumulated deficit | -$9.0M | -$8.9M | |
| Total Stockholders' Deficit | -$297.6K | -$221.2K | -$82.1K |
| Total Liabilities and Stockholders' Deficit | $21.0K | $17.9K | |
| Preferred Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 15.0M shares | 15.0M shares | |
| Preferred Stock, Shares Issued | 15.0M shares | 15.0M shares | |
| Preferred Stock, Shares Outstanding | 15.0M shares | 15.0M shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 2.7B shares | 2.7B shares | |
| Common Stock, Shares, Issued | 1.0B shares | 1.0B shares | |
| Common Stock, Shares, Outstanding | 1.0B shares | 1.0B shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$76.4K | -$95.8K |
| Net change in prepaid expenses | -$3.3K | -$15.9K |
| Common control merger | -$43.3K | |
| Net cash used in operating activities | -$79.7K | -$154.9K |
| Loans from related party | $79.5K | $137.4K |
| Net cash provided by financing activities | $79.5K | $137.4K |
| Net change in cash | -$194 | -$17.5K |
No quarter-by-quarter statement was filed.
What it owns
What NIKA PHARMACEUTICALS, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
Leadership
Who has led NIKA PHARMACEUTICALS, INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerDimitar Slavchev Savov Mar 19, 2025 to Mar 19, 202510
- PresidentDimitar Slavchev Savov Mar 19, 2025 to Mar 19, 202510
- Chief financial officerDimitar Slavchev Savov Mar 19, 2025 to Mar 19, 202510
Board members and other officers (1)
- Board memberDimitar Slavchev Savov Mar 19, 2025 to Mar 19, 202510
Former names
- CENTENNIAL GROWTH EQUITIES INCDec 3, 2020 to Aug 15, 20222
Timeline
- Mar 19, 2025New chief executive Dimitar Slavchev Savov becomes CEO10
- Oct 16, 20248-K Change of auditor11
- Oct 1, 20248-K Change of auditor12
- Aug 27, 20248-K Completed an acquisition or sale13
- May 10, 20248-K Completed an acquisition or sale; Other events14
- Apr 15, 20248-K Completed an acquisition or sale15
- Mar 5, 20248-K Completed an acquisition or sale; Bylaws or fiscal year changed16
- Feb 16, 20248-K Change of auditor17
- Sep 18, 20238-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares18
- Nov 15, 20228-K Executive or director change19
- Nov 1, 20228-K Change of auditor20
- Aug 22, 20228-K Bylaws or fiscal year changed21
- Apr 12, 20228-K Completed an acquisition or sale; Change to shareholders' rights22
Filings
55 filings to the SEC since October 2021: 5 annual reports, 17 quarterly reports, 13 major events, 3 insider forms, 17 other. The latest 20:
- Aug 10, 202610-Q EDGAR
- May 12, 202610-Q EDGAR
- Mar 25, 202610-K EDGAR
- Nov 7, 202510-Q EDGAR
- Aug 14, 202510-Q EDGAR
- May 13, 202510-Q EDGAR
- Apr 16, 2025144 EDGAR
- Mar 31, 202510-K EDGAR
- Mar 19, 20254 EDGAR
- Nov 12, 202410-Q EDGAR
- Nov 1, 202410-Q/A EDGAR
- Oct 16, 20248-K EDGAR
- Oct 8, 2024UPLOAD EDGAR
- Oct 1, 20248-K EDGAR
- Sep 19, 2024RW EDGAR
- Sep 18, 202410-Q FORM-10Q EDGAR
- Sep 16, 2024RW FORM-RW EDGAR
- Sep 12, 2024RW EDGAR
- Aug 27, 20248-K EDGAR
- Aug 14, 2024NT 10-Q FROM 12B-25 EDGAR
The 55 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
8 open-market trades by officers, directors and large owners since October 2021: 1 buys and 7 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 18, 2025 | Savov Dimitar SlavchevCEO, CFO, President | Sale | 2,000,000 | $0.25 | $500.0K | Form 4 |
| Jun 2, 2023 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 3,500,000 | $0.02 | $70.0K | Form 4 |
| Jan 31, 2023 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 1,500,000 | $0.01 | $15.0K | Form 4 |
| Jan 10, 2023 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 6,300,000 | $0.01 | $63.0K | Form 4 |
| Oct 24, 2022 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 3,000,000 | $0.04 | $120.0K | Form 4 |
| Sep 26, 2022 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 1,250,000 | $0.02 | $25.0K | Form 4 |
| Sep 12, 2022 | NIKA PHARMACEUTICALS, INCSecretary | Sale | 7,000,000 | $0.02 | $140.0K | Form 4 |
| Apr 13, 2022 | NIKA PHARMACEUTICALS, INCSecretary | Buy | 11,489,000 | $0.01 | $114.9K | Form 4 |
From Forms 4 filed with the SEC.
SEC filer profile
How NIKA PHARMACEUTICALS, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARNIKA PHARMACEUTICALS, INC1
- CIK0001145604
- Employer ID (EIN)90-029294023
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company23
- Incorporated incolorado23
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address2269 Merrimack Valley Avenue, Henderson, NV 890441
- Phone70232636151
- Shares outstanding1,051,689,224 as of Jul 4, 20269
- Public float$0 as of Mar 9, 20267
- AuditorBoladale Lawal, Lagos, Nigeria PCAOB ID 699323
- On EDGAR sinceDec 3, 20201
- Filings71 in all: 10-Q (17), 8-K (13), 10-K (6), UPLOAD (6), RW (5), NT 10-Q (4), 4 (3), CORRESP (3)1
All 20 form types
10-12G/A (2), 10-Q/A (2), 1-A-W (1), 10-12B (1), 10-12G (1), 10-K/A (1), 144 (1), DEL AM (1), NT 10-K (1), RW WD (1), S-4 (1), S-4/A (1)
- Latest filingsAnnual report (10-K) Mar 25, 2026
Quarterly report (10-Q) Aug 10, 2026
Latest 8-K (8-K) Oct 16, 2024
Risk factors and legal proceedings
Legal proceedings
There are no material claims, actions, suits, proceedings, or investigations that are currently pending or, to the Company’s knowledge, threatened by or against the Company or respecting its operations or assets, or by or against any of the Company’s officers, directors, or affiliates.
The opening of Item 3, Legal Proceedings.23
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARChange of auditor
- 12SEC EDGARChange of auditor
- 13SEC EDGARCompleted an acquisition or sale
- 14
- 15SEC EDGARCompleted an acquisition or sale
- 16
- 17SEC EDGARChange of auditor
- 18
- 19SEC EDGARExecutive or director change
- 20SEC EDGARChange of auditor
- 21SEC EDGARBylaws or fiscal year changed
- 22
- 23